Who are Emtricitabine/tenofovir disoproxil fumarate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Emtricitabine and Tenofovir, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Etravirine (ETR), Doravirine (DOR), Emtricitabine / Tenofovir Disoproxil Pill, efavirenz (drug).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/emtricitabine-tenofovir-disoproxil-fumarate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Emtricitabine/tenofovir disoproxil fumarate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Emtricitabine/tenofovir disoproxil fumarate (Emtricitabine/tenofovir disoproxil fumarate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination. Area: Infectious Disease / Virology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination HIV-1 reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Emtricitabine/tenofovir disoproxil fumarate (Emtricitabine/tenofovir disoproxil fumarate) — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Emtricitabine/tenofovir disoproxil fumarate TARGET	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Oral Tablet	Emtricitabine / Tenofovir Disoproxil Oral Tablet	University of Chicago	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Etravirine (ETR)	Etravirine (ETR)	ViiV Healthcare	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Doravirine (DOR)	Doravirine (DOR)	Walter K. Kraft	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
efavirenz (drug)	efavirenz (drug)	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination class)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Puerto Rico Community Network for Clinical Research on AIDS · 1 drug in this class
The Miriam Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Emtricitabine/tenofovir disoproxil fumarate — Competitive Intelligence Brief. https://druglandscape.com/ci/emtricitabine-tenofovir-disoproxil-fumarate. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab